1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Immunoglobulin Light Chain Deposition: new trials by email Literature Review of Immunoglobulin Light Chain Deposition trials Research Report on Immunoglobulin Light Chain Deposition
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis Bortezomib, Dexamethasone, Ibrutinib - Amyloidosis, Immunoglobulin Light Chain Deposition | Phase 2 | Withdrawn | Mayo Clinic | 2018-03-15 | 2018-03-02 |
Amyloidosis (1)
Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Proteostasis Deficiencies (1)
Bortezomib (1) · Calcium Dobesilate (1) · Dexamethasone (1) · auricularum (1) · dexamethasone 21-phosphate (1) · dexamethasone acetate (1) · ibrutinib (1)
Mayo Clinic (1)
Taimur Sher (1)
P30CA015083 (1)